Biogen Inc. (FRA:IDP)

Market Cap	22.21B +11.2%
Revenue (ttm)	8.58B +4.8%
Net Income	1.37B -0.4%
EPS	9.35 -0.8%
Shares Out	n/a
PE Ratio	16.20
Forward PE	13.88
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40
Average Volume	59
Open	146.25
Previous Close	146.00
Day's Range	146.25 - 146.80
52-Week Range	99.82 - 161.35
Beta	n/a
RSI	50.46
Earnings Date	Feb 6, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: IDP

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD